Itepekimab治疗中重度COPD的遗传关联研究与2a期试验
本研究先通过遗传分析发现IL-33通路功能丧失变异与COPD风险降低相关,功能获得变异与风险增加相关。随后开展随机双盲2a期试验,343例中重度COPD患者随机接受itepekimab 300mg或安慰剂每2周皮下注射。总体人群主要终点未达到,但亚组分析显示Former smoker(戒烟者)中itepekimab降低急性加重率并改善FEV1。
要点
- IL-33通路功能丧失变异与COPD风险降低相关,功能获得变异与风险增加相关
核心结论
- 总体人群主要终点未达到,但亚组分析显示itepekimab在戒烟者中降低急性加重率并改善肺功能。
- 两项3期研究正在进行以确认itepekimab在戒烟者COPD中的疗效和安全性。
研究设计与样本
- 两部分研究:先进行IL-33通路功能丧失和功能获得变异的遗传分析,再开展随机双盲2a期试验。
- 2a期试验在10个国家83个中心进行,343例40-75岁中重度COPD患者随机(1:1)接受itepekimab 300mg或安慰剂。
- 给药方式为每2周两次皮下注射,持续24-52周。
- 主要终点为治疗期间中重度急性加重年化率,关键次要终点为基线至16-24周支气管舒张前FEV1变化。
主要发现
- 治疗中出现的不良事件:itepekimab组135例(78%),安慰剂组136例(80%);最常见为鼻咽炎(16% vs 17%)、支气管炎(10% vs 8%)、头痛(8% vs 13%)、上呼吸道感染(8% vs 9%)。
关键数值与推荐
- 遗传分析显示IL33功能丧失与COPD风险降低相关,IL33和IL1RL1功能获得变异与风险增加相关。
- 2a期试验纳入标准:40-75岁当前或既往吸烟者,COPD诊断至少1年,稳定使用三联或二联吸入维持治疗。
临床怎么用
- 对于戒烟的中重度COPD患者,itepekimab可能降低急性加重率并改善肺功能,但需3期研究确认。
- 当前吸烟者未显示治疗获益,临床使用需考虑吸烟状态。
- 总体人群主要终点未达到,不宜将2a期结果作为普遍推荐依据。
局限性
- 2a期试验样本量较小(343例),主要终点未达到。
- 亚组分析(戒烟者)为预设但非主要分析,结果需谨慎解读。
- 研究周期24-52周,长期疗效和安全性未评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Genetic data implicate IL-33 in asthma susceptibility. Itepekimab, a monoclonal antibody targeting IL-33, demonstrated clinical activity in asthma, with potential in chronic obstructive pulmonary disease (COPD). In this study we first aimed to test the hypothesis that genetic variants in the IL-33 pathway were also associated with COPD. On the basis of the strong association of IL-33 pathway genes with pulmonary diseases like asthma and COPD, we conducted this phase 2a trial to assess the safety and efficacy of itepekimab in patients with moderate-to-severe COPD on a stable regimen of triple-inhaled or double-inhaled background maintenance therapy. METHODS: In this two-part study, genetic analyses of loss-of-function and gain-of-function variants in the IL-33 pathway, previously associated with asthma risk, were initially characterised for COPD. We then did a double-blind, phase 2a trial comparing itepekimab with placebo in patients with moderate-to-severe COPD despite standard therapy, at 83 study sites in ten countries. Patients aged 40-75 years who were current or former smokers, had been diagnosed with COPD for at least 1 year, and were on a stable regimen of triple-inhaled or double-inhaled background maintenance therapy, were randomly assigned (1:1) to receive itepekimab 300 mg or placebo, administered as two subcutaneous injections every 2 weeks for 24-52 weeks. The primary endpoint of the phase 2a trial was annualised rate of moderate-to-severe acute exacerbations of COPD during the treatment period. The key secondary outcome was change in prebronchodilator FEV1 from baseline to weeks 16-24. Prespecified subgroup analyses were done for each of the endpoints, including by smoking status. Efficacy and safety analyses were done in all participants who received at least one dose of assigned treatment (modified intention-to-treat population). This trial is registered at ClinicalTrials.gov (NCT03546907). FINDINGS: Genetic analyses demonstrated association of loss of function in IL33 with reduced COPD risk, and gain of function in IL33 and IL1RL1 variants with increased risk. Subsequent to this, in the phase 2 trial, 343 patients were randomly assigned to placebo (n=171) or itepekimab (n=172) from July 16, 2018, to Feb 19, 2020. Annualised rates of acute exacerbations of COPD were 1·61 (95% CI 1·32-1·97) in the placebo group and 1·30 (1·05-1·61) in the itepekimab group (relative risk [RR] 0·81 [95% CI 0·61-1·07], p=0·13), and least squares mean prebronchodilator FEV1 change from baseline to weeks 16-24 was 0·0 L (SD 0·02) and 0·06 L (0·02; difference 0·06 L [95% CI 0·01-0·10], p=0·024). When analysis was restricted to former smokers, treatment with itepekimab was associated with nominally significant reductions in acute exacerbations of COPD (RR 0·58 [95% CI 0·39-0·85], p=0·0061) and FEV1 improvement (least squares mean difference 0·09 L [0·02-0·15], p=0·0076) compared with placebo. Current smokers treated with itepekimab showed no treatment benefit versus placebo for exacerbations (RR 1·09 [0·74-1·61], p=0·65) or FEV1 (least squares mean difference 0·02 [-0·05 to 0·09], p=0·54). Treatment-emergent adverse events (TEAEs) occurred in 135 (78%) patients in the itepekimab group and 136 (80%) in the placebo group. The most common TEAEs were nasopharyngitis (28 [16%] in the itepekimab group vs 29 [17%] in the placebo group), bronchitis (18 [10%] vs 14 [8%]), headache (14 [8%] vs 23 [13%]), and upper respiratory tract infection (13 [8%] vs 15 [9%]). INTERPRETATION: The primary endpoint in the overall population was not met, subgroup analysis showed that itepekimab reduced exacerbation rate and improved lung function in former smokers with COPD. Two phase 3 clinical studies are ongoing to confirm the efficacy and safety profile of itepekimab in former smokers with COPD. FUNDING: Sanofi and Regeneron Pharmaceuticals.
引用
- Rabe KF, Celli BR, Wechsler ME, et al. Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. Lancet Respir Med. 2021. PMID: 34302758. doi:10.1016/S2213-2600(21)00167-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。